Citizens Financial Group Inc Enlivex Therapeutics Ltd. Transaction History
Citizens Financial Group Inc
- $7.13 Billion
- Q3 2025
A detailed history of Citizens Financial Group Inc transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Citizens Financial Group Inc holds 231,424 shares of ENLV stock, worth $240,680. This represents 0.0% of its overall portfolio holdings.
Number of Shares
231,424Holding current value
$240,680% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ENLV
# of Institutions
26Shares Held
2.81MCall Options Held
79.1KPut Options Held
0-
Armistice Capital, LLC New York, NY1.41MShares$1.47 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny612KShares$636,6880.0% of portfolio
-
Morgan Stanley New York, NY219KShares$227,9140.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny168KShares$175,1270.0% of portfolio
-
Jane Street Group, LLC New York, NY61.1KShares$63,4940.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $19.1M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...